27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Self-reported changes in physical and mental health by members are an important dimension by which the quality of a Medicare Advantage (MA) plan is rated by the Centers for Medicare & Medicaid Services. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The mechanism of action of benzodiazepines is through the modulation of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that suppresses the central nervous system (CNS); the drugs have efficacy for short-term use (less than 1 month), but patients can develop a tolerance and dependence with long-term use.2 The benefits of benzodiazepines decrease over time and there are increased associated risks such as cognitive decline, accidental injuries, falls, and increased rates of hospital admissions and ED visits.2 Patients can also have paradoxical anxiety while on benzodiazepines.3 Studies have shown that long-term use of benzodiazepines increases the risk of dementia.4,5 Recent clinical practice guidelines recommend deprescribing benzodiazepines for older adults (age 65 years or older) for use in insomnia, and the American Geriatric Society (AGS) BEERs Criteria recommend avoidance of benzodiazepines in older adults because of the increased risk of adverse reactions such as falls and fractures.1,6 The AGS does say that benzodiazepines may be appropriate for use in older adults in certain circumstances such as ethanol withdrawal, and periprocedural anesthesia.6 The FDA has cautioned providers about prescribing benzodiazepines in patients using opioids but does not recommend withholding medications used for opioid use disorder in patients taking benzodiazepines.7,8 NPs can be instrumental in adequately treating anxiety and insomnia disorders with nonpharmacologic interventions (such as yoga and sleep hygiene) as well as with other medication classes that are not benzodiazepines. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Recent studies indicate that having a billed AWV is associated with increases in preventive care services such as vaccinations, cancer screening, and dementia diagnosis. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
I’ll be applying soon. Claire: Maddie, what do you think will be different for you when you come to visits with us versus visits with an adult provider? 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
As has been noted, Alzheimer’s and related dementias are underdiagnosed and when diagnoses are made, they are too often undisclosed by clinicians: studies suggest that fewer than half of individuals report being told of their diagnoses (Alzheimer’s Association, 2015). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Better understanding of sociodemographic factors of our patient group is key to improving equity of care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There are many types of Dementia‐Friendly Communities (DFCs), and communities define and implement them in different ways. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neighborhood disadvantage was selectively associated with cognitive measures heavily influenced by executive function, namely using an efficient word generation strategy, and incorporating feedback to guide problem-solving. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The most successful amyloid-targeting treatments achieve modest plaque reduction with marginal clinical benefit and significant adverse effects. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The dominant research paradigm for Alzheimer's disease has focused on amyloid-beta plaqueremoval for over three decades, producing no curative therapy despite billions of dollars ofinvestment. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Este trabalho é uma revisão de literatura que explora a relação entre mecanismos epigenéticos e a Doença de Alzheimer (DA), uma doença neurodegenerativa caracterizada por perda de memória e dificuldades cognitivas. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Apolipoprotein E-4 (APOE-4), serotonin transporter gene (SLC6A4), and single nucleotide polymorphisms (SNPs) of glucocerebrosidase (GBA) are some of the main altered genes in AD, PDD and DLB. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease is a neurological illness that impacts mental and emotional functions functions, has become a global concern due to its increasing prevalence. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Bệnh Alzheimer (AD) có căn nguyên không rõ ràng. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
ResumenLa llegada de los anticuerpos monoclonales lecanemab y donanemab marca un cambio de paradigma en el tratamiento de la enfermedad de Alzheimer, transitando del nihilismo terapéutico a la era de las terapias modificadoras de la enfermedad. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer disease (AD) pathology affects the transentorhinal/entorhinal region early but whether entorhinal cortex (EC) astrocytes are causal drivers or therapeutic targets remains unresolved. 5 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Full or partial trisomy of human chromosome 21 results in dysregulation of gene expression, leading to the manifestation of specific phenotypes described in individuals with Down syndrome (DS). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease, AD, has been a difficult problem for relevant experts and patients since its discovery. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lecanemab and Donanemab are two new FDA-approved antiamyloid immunotherapies that are Alzheimer disease modifying agents. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Canada’s Drug Agency (CDA-AMC) recommends that Leqembi be reimbursed by public drug plans for the treatment of adult patients in the early stages of Alzheimer disease (AD) (i.e., mild cognitive impairment [MCI] or mild dementia) who have evidence of amyloid in the brain and who are APOE epsilon 4 (APOE4) noncarriers or heterozygotes, if certain conditions are met. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
La carta al editor presenta recomendaciones actualizadas para el uso de donanemab en la enfermedad de Alzheimer (EA), basadas en su papel dentro de la hipótesis de la cascada amiloide. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by memory loss, cognitive decline, and behavioral changes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mit der Einführung neuer Alzheimer-Therapien wie den Anti-Amyloid-Antikörpern Lecanemab und Donanemab rückt ein bislang wenig bekanntes, aber hochaktuelles Phänomen in den Fokus: ARIA – Amyloid-related Imaging Abnormalities. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →